Many countries, including the United States, Japan and Europe, have approved several anti-PD-1/PD-L1 therapies for treating multiple tumors, including head and neck cancer, melanoma, lung cancer, and ovarian cancer11–13. The gene discussed is CD274; the disease is melanoma.